‘A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer’-Reference-Cited by-同舟云学术

‘A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer’

Published:2005-12-13 Issue:1 Volume:94 Page:69-73
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Bennouna J,Perrier H,Paillot B,Priou F,Jacob J H,Hebbar M,Bordenave S,Seitz J F,Cvitkovic F,Dorval E,Malek K,Tonelli D,Douillard J Y

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6602913.pdf

Reference24 articles.

1. Ansfield FJ, Kallas GJ, Singson JP (1983) Phase I-II studies of oral tegafur (ftorafur). J Clin Oncol 1: 107–110

2. Anttila MI, Sotaniemi EA, Kairaluoma MI, Mokka RE, Sundquist HT (1983) Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol 10: 150–153

3. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Müller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD, for the Swiss Group for Clinical Cancer Research (2002b) Phase II study of capecitabine and oxaliplatin in first- and second line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20: 1759–1766

4. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P (2002a) Patient preference and pharmacokinetics of oral modulated UFT vs intravenous fluorouracil and leucovorin trial in advanced colorectal cancer. Eur J Cancer 38: 349–358

5. Carmichael J, Popiela T, radstone D, Falk S, Borner M, Oza M, Skovsgaard T, Munier S, Martin S (2002) Randomized compartive study of Tegafur/Uracil and Oral Leucovorin vs parenteral Flourouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 17: 3617–3627

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tegafur–Uracil/Leucovorin Plus Oxaliplatin (TEGAFOX) as Consolidation Regimen after Short-Course Radiotherapy Is Effective for Locally Advanced Rectal Cancer;Journal of Clinical Medicine;2022-05-22

2. Randomized phase II study of tegafur–uracil/leucovorin versus tegafur–uracil/leucovorin plus oxaliplatin after curative resection of high-risk stage II/III colorectal cancer (SOAC-1101 trial);International Journal of Colorectal Disease;2021-03-14

3. Oral drugs in the treatment of metastatic colorectal cancer;Therapeutic Advances in Medical Oncology;2021-01

4. Current Scenario in Structure and Ligand-Based Drug Design on Anti-colon Cancer Drugs;Current Pharmaceutical Design;2019-01-15

5. FOLFOX4 With Cetuximab vs. UFOX With Cetuximab as First-Line Therapy in Metastatic Colorectal Cancer: The Randomized Phase II FUTURE Study;Clinical Colorectal Cancer;2014-03